Get started
Author

Bernt Johan von Scholten

Observed names: B. J. von Scholten, B. Johan Von Scholten, B. Scholten, B.J. Von Scholten, B.J.V. Scholten, BERNT JOHAN VON SCHOLTEN, BJ Scholten, Bernt Johan von Scholten, Bernt J von Scholten, Bernt J. Scholten, Bernt J. von Scholten, Bernt J. von Scholten J. von Scholten, Bernt Johan Von Scholten, Bernt Johan von Scholten, Scholten Bernt Johan von, Scholten, Bernt, von Scholten, Bernt, von Scholten, Bernt Johan
Observed institutions: University of Copenhagen, Steno Diabetes Centers, Novo Nordisk (Denmark), Aarhus University, Copenhagen University Hospital, Rigshospitalet, Steno Diabetes Center Copenhagen, Aalborg University
ORCID: 0000-0002-1489-0636
Observed ORCID: 0000-0002-1489-0636
OpenAlex ID: A5038074967
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
2020 · Nete Tofte, Morten Lindhardt, et al. · The Lancet Diabetes & Endocrinology · 264
PDF
Global Changes in Food Supply and the Obesity Epidemic
2016 · Emilie H. Zobel, Tine W. Hansen, et al. · Current Obesity Reports · 226
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
2021 · Matthias von Herrath, Stephen C Bain, et al. · The Lancet Diabetes & Endocrinology · 192
PDF
Current and future therapies for type 1 diabetes
2021 · Bernt Johan von Scholten, Frederik F. Kreiner, et al. · Diabetologia · 157
PDF
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
2018 · Johannes F. E. Mann, Vivian Fonseca, et al. · Circulation · 147
Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer
2017 · Jens Oellgaard, Signe Abitz Winther, et al. · Current Pharmaceutical Design · 140
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives
2022 · Frederik Flindt Kreiner, Jordan M Kraaijenhof, et al. · Expert Review of Clinical Immunology · 113
The effect of liraglutide on renal function: A randomized clinical trial
2016 · Bernt J. von Scholten, Frederik Persson, et al. · Diabetes Obesity and Metabolism · 106
Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes
2019 · Regitse H. Christensen, Bernt Johan von Scholten, et al. · Cardiovascular Diabetology · 104
PDF
Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: A systematic review and meta‐analysis
2020 · Natja Launbo, Emilie H. Zobel, et al. · Obesity Reviews · 81
Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes
2015 · Bernt J. von Scholten, Philip Hasbak, et al. · Diabetologia · 79
PDF
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
2014 · B. J. von Scholten, M. Lajer, et al. · Diabetic Medicine · 74
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
2021 · Frederik Persson, Stephen C Bain, et al. · Diabetes Care · 73
PDF
Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?
2020 · Regitse Højgaard Christensen, Bernt Johan von Scholten, et al. · Therapeutic Advances in Endocrinology and Metabolism · 72
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes
2015 · Bernt Johan von Scholten, Tine Willum Hansen, et al. · Journal of Diabetes and its Complications · 69
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial
2017 · Laszlo Hegedüs, Steven I. Sherman, et al. · Diabetes Care · 68
Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics
2016 · Peter Godsk Jørgensen, Magnus T Jensen, et al. · Diabetes and Vascular Disease Research · 68
PDF
Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria
2018 · Daniel G.K. Rasmussen, Tine W. Hansen, et al. · Diabetes Care · 66
PDF
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial
2018 · Matthew P. Gilbert, Stephen C. Bain, et al. · Annals of Internal Medicine · 62
Effect of large weight reductions on measured and estimated kidney function
2017 · Bernt Johan von Scholten, Frederik Persson, et al. · BMC Nephrology · 61
PDF
Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria
2015 · Bernt Johan von Scholten, Henrik Reinhard, et al. · Journal of Diabetes and its Complications · 61
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial
2017 · Bernt Johan von Scholten, Frederik Persson, et al. · Diabetes Obesity and Metabolism · 60
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
2021 · Emilie H. Zobel, Rasmus S. Ripa, et al. · Scientific Reports · 59
PDF
Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes
2019 · Regitse H. Christensen, Christian S. Hansen, et al. · Diabetes Obesity and Metabolism · 57
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
2017 · Emilie H. Zobel, Bernt Johan von Scholten, et al. · Cardiovascular Diabetology · 55
PDF
Works count: 132
Citation count: 3,570
H-index: 35
I10-index: 61
Year
Topic
Type